Hep E vax provides 4 years of protection; Zimbabwe to launch HIV jab trial;

> Novavax ($NVAX) has appointed Brian Rosen as its VP of government affairs. Release

> Targovax is expanding expand an ongoing Phase I/II study of its cancer vaccine candidate. Release

> Scientists in Zimbabwe are preparing to launch the country's first-ever HIV vaccine trial. More

> A vaccine against hepatitis E provided protection against the virus for more than 4 years, researchers say. Report

And Finally... H7N9 bird flu has the makings of a pandemic virus, scientists caution. More

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.